Megan L. Lawlor

Megan L. Lawlor

Auto-generated profile, based on publicly available information

Megan L. Lawlor

Washington University in Saint Louis, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine and Ultrasound

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2022 in American Journal of Obstetrics & Gynecology MFM
Verified
Journal Article
Closed access
MLMegan L. Lawlor
Megan L. Lawlor
JGJennifer M. Goldkamp
Jennifer M. Goldkamp
ABAshley Boerrigter
Ashley Boerrigter
CJChristine Jakes
Christine Jakes
RPRachel Pyon
Rachel Pyon
RARajeev Aurora
Rajeev Aurora

30 March 2024 in medRxiv
Verified
Preprint
Open access
PDF file
CTCassandra J. Trammel
Cassandra J. Trammel
AAArpana Agrawal
Arpana Agrawal
RBRyan Bogdan
Ryan Bogdan
MLMegan Lawlor
Megan Lawlor
NRNandini Raghuraman
Nandini Raghuraman
ECEbony B. Carter
Ebony B. Carter
OBJECTIVE: Evaluate associations between prenatal cannabis use (PCU) and perinatal outcomes. METHODS: We performed an interval analysis of a prospective cohort study of pregnant individuals with pre-pregnancy cannabis use and negative self-report of nicotine use, comparing those who continued cannabis through pregnancy with those who stopped. Patients underwent interviews and urine drug screening for cannabis and cotinine, a nicotine metabolite, in each trimester. The primary outcome was small for gestational age (SGA) at delivery. Secondary outcomes included antenatal and postpartum complications, mode of delivery, and neonatal outcomes. Secondary analyses included stratification by intensity of cannabis use and urinary cotinine positivity. RESULTS: Birthing persons with PCU differed in age (25.5 vs 27.8 years, p=0.001), body mass index (BMI; 27.4 vs 30.9, p=0.001), area deprivation index percentiles (92% PCU vs 88%, p=0.013), cotinine positivity (42.8% vs 10.8%, p<0.001), Hispanic ethnicity (2% vs 7.2%, p=0.009), and education attainment beyond high school (29.4% vs 50%, p<0.001) compared to controls. Birthing person outcomes did not differ. Risks of SGA and other neonatal outcomes did not differ when adjusted for confounders on initial analysis, or with stratification by intensity of cannabis use. Despite negative self-report for nicotine, 42.8% of PCU patients tested positive for cotinine (PCU+c). PCU+c was associated with increased risk of SGA and birthweight less than the 5 th percentile, compared to PCU cases without nicotine exposure (17.4% vs 8.3%, aRR 2.7 [1.21-5.38], 35.8% vs 18.6%, aRR 2.4 [1.51-3.48]), and controls (35.8% vs 12.9%, aRR 2.75 [1.64-4.13]). Cotinine-negative PCU patients and controls did not differ. CONCLUSION: PCU was not independently associated with adverse birthing person outcomes. Many patients demonstrated nicotine exposure, either via inadvertent exposure or undisclosed use. While neonates exposed to cannabis alone did not differ from unexposed neonates, those exposed to both cannabis and nicotine were at increased risk of SGA.

6 November 2016 in Case Reports in Obstetrics and Gynecology
Verified
Journal Article
Open access
PDF file
MLMegan L. Lawlor
Megan L. Lawlor
ACAgatha S. Critchfield
Agatha S. Critchfield
Intrahepatic cholestasis of pregnancy (ICP) is a complication of pregnancy resulting in elevation of serum bile acid levels. ICP is often associated with underlying liver disease, including hepatitis C. Bile acids in relationship to the acute infection of hepatitis C virus have not yet been delineated in the literature. A 26-year-old gravida 4 para 2103 with dichorionic, diamniotic twin gestation and history of intravenous drug abuse developed ICP in the setting of acute hepatitis C infection. In addition to clinical symptoms of pruritus and right upper quadrant pain, she developed severe elevation in bile acids, 239 micromol/L, and transaminitis aspartate aminotransferase 1033 U/L, and alanine aminotransferase 448 U/L. She received ursodeoxycholic acid and antenatal testing was performed. Patient delivered vaginally at 33-week gestation following preterm rupture of membranes. Neonates were admitted to NICU and had uncomplicated neonatal courses. In the setting of ICP with significant transaminitis and severe elevation of bile acids, consideration of acute viral hepatitis is important, especially considering the worsening opioid epidemic and concurrent increase in intravenous drug use in the United States. Further study is needed regarding the acute form of HCV infection and its effect on ICP and associated bile acids.

1 May 2017 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
PDF file
MLMegan Lawlor
Megan Lawlor
KMKristen McQuerry
Kristen McQuerry
NCNiraj Chavan
Niraj Chavan
LSLori Shook
Lori Shook
ACAgatha Critchfield
Agatha Critchfield
Neonatal Opioid Withdrawal Syndrome (NOWS) is a significant public health problem. Care-By-Parent (CBP) is a model for mothers to room-in with their opioid-exposed infants during inpatient observation for postnatal development of NOWS. The purpose of this study is to determine if CBP is associated with a reduction in treatment-requiring NOWS. We performed a retrospective, case control study of pregnant women enrolled in a combined prenatal and medication assisted treatment (MAT) program for opioid-dependent patients. Patients stable on MAT (as indicated by appropriate urine drug screen at Labor & Delivery admission) who participated in CBP were matched by gestational age, smoking and breastfeeding status with controls also stable in the combined prenatal/MAT program. Fisher Exact Test, ANOVA and logistic regression were performed. Primary outcome was diagnosis of treatment-requiring NOWS in neonates. Forty women met inclusion criteria (20 cases, 20 controls). There were no differences in age, gravidity, parity, birth weight, Apgar scores, or buprenorphine dose (P>.05). For the primary outcome, there was a statistically significant reduction in the rate of treatment requiring NOWS among cases vs controls (OR 0.08 95% CI 0.01-0.71). Significant difference was noted in patient time in program (cases vs controls, 19 vs 14 weeks, P=0.02) however, logistic regression demonstrated that the time in program did not affect the rate of NOWS (OR 0.99 95% CI 0.88-1.12). CBP significantly reduces the rate of treatment requiring NOWS. This approach decreases NICU admissions, increases maternal-child bonding and has the potential for alleviating maternal substance abuse patterns.